Intervention

canagliflozin

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions5

Lead sponsors shown4

Clinical trials

4 shown

Renal Mechanism of SGLT2 InhibitionNCT05507892 · 2022-10-10

ACTIVE_NOT_RECRUITING

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 DiabetesNCT02912455 · 2017-01-05

Canagliflozin-Mealtime Insulin RescueNCT02624908 · 2016-01-01

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin InfusionNCT02673138 · 2016-01-01

Common conditions

Diabetes Mellitus, Type 22 Diabetic Kidney Disease1 Obesity1 Type 1 Diabetes1 Type 2 Diabetes1

Leading sponsors

Foundation for Atlanta Veterans Education and Research, Inc.1 The Cleveland Clinic1 University of Colorado, Denver1 Yale University1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

UNKNOWN1

Phase mix

PHASE42

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.